Arcus Biosciences (RCUS) Current Assets (2017 - 2026)

Arcus Biosciences' Current Assets history runs 10 years deep, the most recent figure standing at $844.0 million for Q1 2026.

• In Q1 2026, Current Assets fell 18.14% year-over-year to $844.0 million; the TTM figure through Mar 2026 stood at $844.0 million (down 18.14% YoY), while the FY2025 annual figure was $1.0 billion, down 0.89% from the prior year.
• Current Assets for Q1 2026 stood at $844.0 million, down from $1.0 billion in the prior quarter.
• The five-year high for Current Assets was $1.3 billion in Q1 2022, with the low at $831.0 million in Q4 2023.
• The 5-year median for Current Assets is $1.0 billion (2024), against an average of $1.0 billion.
• The sharpest annual moves came in 2022 and 2025: Current Assets jumped 101.93% in 2022, then declined 23.96% in 2025.
• Arcus Biosciences' Current Assets stood at $1.1 billion in 2022, then retreated by 22.12% to $831.0 million in 2023, then climbed by 22.26% to $1.0 billion in 2024, then fell by 0.89% to $1.0 billion in 2025, then dropped by 16.19% to $844.0 million in 2026.
• Business Quant data shows RCUS's Current Assets at $844.0 million in Q1 2026, $1.0 billion in Q4 2025, and $857.0 million in Q3 2025.